Candidiasis: Clinical Trials

22 trials for Candidiasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed. 22 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Completed 22
Phase 21Completed 1

Follow Candidiasis: new trials by email Literature Review of Candidiasis trials Research Report on Candidiasis

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers
CanProFem-AK - Candidosis Vaginal
Phase 1CompletedIndustrial Microbiology LLP202024-06-012024-08-02
Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Nitric Oxide - Candidiasis, Oral
Phase 1CompletedSanotize Research and Development corp.62024-01-202024-07-10
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection
Phase 1CompletedScynexis, Inc.52023-07-122025-08-08
The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles
Chitosan - Oral Thrush
Phase 1CompletedYasmine gamil802023-01-102023-10-10
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg - Aspergillus Infections, Candida Infections
Phase 1CompletedChong Kun Dang Pharmaceutical242015-09-012020-03-18
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
Lcr Regenerans® vaginal capsules, Lcr Regenerans® vaginal tablet - Candidiasis, Vulvovaginal
Phase 1CompletedBiose342015-07-012018-02-05
A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers
Lozanoc 50mg, Sporanox 100mg - Superficial Mycoses, Dermatomycoses
Phase 1CompletedBoryung Pharmaceutical Co., Ltd242015-07-012016-03-04
Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida
Medium-Chain Triglyceride (MCT) Oil - Candida Infection, Premature Infant
Phase 1CompletedJoseph Bliss122014-06-052022-06-14
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Rituximab - Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)72014-04-292026-10-26
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis
Phase 1 / Phase 2CompletedNovaDigm Therapeutics, Inc.1882013-07-012018-07-18
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
TOL-463 Vaginal ovule, TOL-463 Vaginal gel - Vaginal Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)262013-04-012014-05-16
Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation
Micafungin - Invasive Candidiasis
Phase 1CompletedKevin Watt182013-01-012019-11-05
The Effect of Palatal Brushing on Denture Stomatitis
Palatal brushing - Denture Stomatitis
Phase 1CompletedUniversité de Montréal482012-07-012014-01-22
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM - Staphylococcal Infections, Yeast Infections
Phase 1CompletedNovaDigm Therapeutics, Inc.1642011-09-012020-03-04
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
NDV-3 investigational vaccine - Staphylococcal Infections, Candidiasis
Phase 1CompletedNovaDigm Therapeutics, Inc.402011-01-012012-05-22
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
PEV7C1, PEV7C9, PEV7B2 - Recurrent Vulvovaginal Candidiasis
Phase 1CompletedPevion Biotech Ltd482010-03-012012-12-24
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
Fluconazole Loading Dose, Fluconazole Loading Dose & High Dose - Candidiasis
Phase 1CompletedDaniel Benjamin132008-11-012018-11-05
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Micafungin - Oropharyngeal Candidiasis, Candidemia
Phase 1CompletedAstellas Pharma Inc842007-10-142024-11-18
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Micafungin (Mycamine) - Invasive Candidiasis, Esophageal Candidiasis
Phase 1CompletedAstellas Pharma Inc92007-10-012014-08-20
Voriconazole to Prevent Systemic Fungal Infections in Children
Voriconazole - Aspergillosis, Candidiasis
Phase 1CompletedNational Cancer Institute (NCI)482000-06-012008-03-04

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Candidiasis, Vulvovaginal (6)  ·  Mycoses (5)  ·  Candidiasis, Oral (4)  ·  Aspergillosis (3)  ·  Candidemia (3)  ·  Candidiasis, Invasive (3)  ·  Fungemia (3)  ·  Torulopsis (3)  ·  Staphylococcal Infections (2)  ·  AIDS-Related Complex (1)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Candidiasis, Chronic Mucocutaneous (1)  ·  Dermatomycoses (1)  ·  Fever (1)

Broader conditions

Bacterial Infections and Mycoses (22)  ·  Infections (22)  ·  Mycoses (17)  ·  Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Female Urogenital Diseases (6)  ·  Genital Diseases, Female (6)  ·  Invasive Fungal Infections (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Vaginal Diseases (6)  ·  Vulvar Diseases (6)  ·  Vulvitis (6)

Interventions

Micafungin (4)  ·  Fluconazole (2)  ·  Voriconazole (2)  ·  Chitosan (1)  ·  Itraconazole (1)  ·  Methadone (1)  ·  Nitric Oxide (1)  ·  Oils (1)  ·  Rituximab (1)  ·  ibrexafungerp (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  NovaDigm Therapeutics, Inc. (3)  ·  Astellas Pharma Inc (2)  ·  National Cancer Institute (NCI) (2)  ·  Biose (1)  ·  Boryung Pharmaceutical Co., Ltd (1)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Daniel Benjamin (1)  ·  Industrial Microbiology LLP (1)  ·  Joseph Bliss (1)  ·  Kevin Watt (1)  ·  Pevion Biotech Ltd (1)  ·  Sanotize Research and Development corp. (1)  ·  Scynexis, Inc. (1)  ·  Université de Montréal (1)

Countries

United States (14)  ·  Canada (2)  ·  South Korea (2)  ·  Brazil (1)  ·  Egypt (1)  ·  France (1)  ·  Kazakhstan (1)  ·  South Africa (1)  ·  Switzerland (1)

Top investigators

Christa S Zerbe, M.D. (1)  ·  Cobb M (1)  ·  Daniel Benjamin, MD (1)  ·  Elham Emami, DDS, PhD (1)  ·  Giuseppe Pantaleo, Prof (1)  ·  Joel Epstein (1)  ·  John P. Hennessey, Jr., Ph.D. (1)  ·  Joseph M Bliss, MD, PhD (1)  ·  Keith Moore, PHARMMD (1)  ·  Kevin Watt, MD (1)  ·  Kyun-Seop Bae, M.D., Ph.D. (1)  ·  Letts A (1)  ·  Raphael F de Souza, DDS, PhD (1)  ·  Rolf Pokorny, MD, MSc (1)

Results publications

PMID 29596218, PMID 29697768, PMID 32468741, PMID 38321454

NIH funding

2014 (1)